![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EPHA4 |
Gene summary for EPHA4 |
![]() |
Gene information | Species | Human | Gene symbol | EPHA4 | Gene ID | 2043 |
Gene name | EPH receptor A4 | |
Gene Alias | EK8 | |
Cytomap | 2q36.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R452 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2043 | EPHA4 | CCI_1 | Human | Cervix | CC | 8.54e-10 | 5.45e-01 | 0.528 |
2043 | EPHA4 | CCI_3 | Human | Cervix | CC | 5.89e-03 | 5.91e-01 | 0.516 |
2043 | EPHA4 | Tumor | Human | Cervix | CC | 2.81e-05 | 2.79e-01 | 0.1241 |
2043 | EPHA4 | sample3 | Human | Cervix | CC | 4.30e-11 | 2.96e-01 | 0.1387 |
2043 | EPHA4 | T3 | Human | Cervix | CC | 3.59e-13 | 2.98e-01 | 0.1389 |
2043 | EPHA4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.56e-02 | -2.55e-01 | 0.0155 |
2043 | EPHA4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.24e-08 | -5.56e-01 | -0.1808 |
2043 | EPHA4 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.32e-06 | -3.34e-01 | -0.1464 |
2043 | EPHA4 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.83e-03 | -3.27e-01 | -0.1001 |
2043 | EPHA4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.22e-21 | -5.84e-01 | 0.3859 |
2043 | EPHA4 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.55e-06 | -6.21e-01 | 0.2585 |
2043 | EPHA4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.32e-30 | -6.35e-01 | 0.3005 |
2043 | EPHA4 | F007 | Human | Colorectum | FAP | 1.29e-02 | -3.67e-01 | 0.1176 |
2043 | EPHA4 | A002-C-010 | Human | Colorectum | FAP | 1.98e-02 | -1.20e-01 | 0.242 |
2043 | EPHA4 | A015-C-203 | Human | Colorectum | FAP | 1.15e-17 | -3.31e-01 | -0.1294 |
2043 | EPHA4 | A015-C-204 | Human | Colorectum | FAP | 8.55e-06 | -3.61e-01 | -0.0228 |
2043 | EPHA4 | A002-C-201 | Human | Colorectum | FAP | 7.90e-07 | -2.01e-01 | 0.0324 |
2043 | EPHA4 | A002-C-203 | Human | Colorectum | FAP | 6.90e-04 | -3.04e-01 | 0.2786 |
2043 | EPHA4 | A001-C-119 | Human | Colorectum | FAP | 1.57e-02 | -3.53e-01 | -0.1557 |
2043 | EPHA4 | A001-C-108 | Human | Colorectum | FAP | 8.90e-09 | -3.14e-01 | -0.0272 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0050804 | Colorectum | CRC | modulation of chemical synaptic transmission | 70/2078 | 439/18723 | 1.15e-03 | 1.33e-02 | 70 |
GO:0099177 | Colorectum | CRC | regulation of trans-synaptic signaling | 70/2078 | 440/18723 | 1.23e-03 | 1.38e-02 | 70 |
GO:00610012 | Colorectum | CRC | regulation of dendritic spine morphogenesis | 13/2078 | 47/18723 | 1.39e-03 | 1.52e-02 | 13 |
GO:00507732 | Colorectum | CRC | regulation of dendrite development | 22/2078 | 103/18723 | 1.85e-03 | 1.88e-02 | 22 |
GO:19029594 | Colorectum | CRC | regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process | 5/2078 | 10/18723 | 2.61e-03 | 2.40e-02 | 5 |
GO:0099175 | Colorectum | CRC | regulation of postsynapse organization | 19/2078 | 90/18723 | 4.18e-03 | 3.41e-02 | 19 |
GO:0043410 | Colorectum | CRC | positive regulation of MAPK cascade | 72/2078 | 480/18723 | 4.85e-03 | 3.74e-02 | 72 |
GO:0021953 | Colorectum | CRC | central nervous system neuron differentiation | 29/2078 | 162/18723 | 6.36e-03 | 4.62e-02 | 29 |
GO:00519621 | Colorectum | CRC | positive regulation of nervous system development | 44/2078 | 272/18723 | 6.71e-03 | 4.77e-02 | 44 |
GO:19052453 | Colorectum | CRC | regulation of aspartic-type peptidase activity | 5/2078 | 12/18723 | 6.79e-03 | 4.77e-02 | 5 |
GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:1903362111 | Esophagus | ESCC | regulation of cellular protein catabolic process | 188/8552 | 255/18723 | 5.12e-20 | 6.62e-18 | 188 |
GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:1903050111 | Esophagus | ESCC | regulation of proteolysis involved in cellular protein catabolic process | 163/8552 | 221/18723 | 1.44e-17 | 1.27e-15 | 163 |
GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa043604 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa043605 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa043606 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
hsa043607 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa043608 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
hsa0436011 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
hsa0436021 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
hsa0436031 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Cervix | CC |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | Cervix | CC |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | Cervix | CC |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | Cervix | CC |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | CRC | AD |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | AD |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | AD |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | AD |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | ADJ |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | ADJ |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | CRC | ADJ |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | FAP |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | FAP |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | Healthy |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | Healthy |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | Healthy |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | MSI-H |
EFNA3 | EPHA4 | EFNA3_EPHA4 | EPHA | CRC | MSI-H |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA4 | SNV | Missense_Mutation | novel | c.2934G>C | p.Gln978His | p.Q978H | P54764 | protein_coding | tolerated(0.45) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
EPHA4 | SNV | Missense_Mutation | rs376275374 | c.2182C>T | p.Arg728Cys | p.R728C | P54764 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA4 | SNV | Missense_Mutation | c.896N>G | p.Ser299Cys | p.S299C | P54764 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EPHA4 | SNV | Missense_Mutation | rs140023331 | c.2918N>A | p.Arg973Gln | p.R973Q | P54764 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA4 | SNV | Missense_Mutation | novel | c.1474N>T | p.Arg492Trp | p.R492W | P54764 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA4 | SNV | Missense_Mutation | c.701T>C | p.Val234Ala | p.V234A | P54764 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EPHA4 | insertion | Nonsense_Mutation | novel | c.574_575insAATGAAATTAATCTTGATGAAAGACCTCTTTATTTCTC | p.Ile192LysfsTer2 | p.I192Kfs*2 | P54764 | protein_coding | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
EPHA4 | insertion | Frame_Shift_Ins | novel | c.210_211insTGGGGCTTAGTGCGAGTAAT | p.Gln71TrpfsTer12 | p.Q71Wfs*12 | P54764 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
EPHA4 | insertion | In_Frame_Ins | novel | c.208_209insCCATATTGCAGTTTTTTC | p.Tyr70delinsSerIleLeuGlnPhePheHis | p.Y70delinsSILQFFH | P54764 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
EPHA4 | SNV | Missense_Mutation | c.1900N>A | p.Glu634Lys | p.E634K | P54764 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2043 | EPHA4 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TYROSINE KINASE | inhibitor | CHEMBL24828 | VANDETANIB | |
2043 | EPHA4 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TYROSINE KINASE | inhibitor | 249565821 |
Page: 1 |